Risk Stratification in Chronic Lymphocytic Leukemia
The Role of the Clinical Laboratory
CLL: Fragile Cells and Time to Treatment
November 2008
A very interesting observation by Nowakowski and colleagues was that the number of fragile cells was actually related to the time of treatment in these patients. Those cases with numerous fragile cells failed to reach a 50% treatment mark up to 12 years post-diagnosis, whereas those who had few fragile cells progressed more rapidly to treatment, i.e., reaching a 50% point at approximately 6 years.
Fragile Cells |
Jump to section:
- Introduction
- Goals Today
- Risk Assessment
- Risk Assessment in CLL
- CLL Rai Stage: Treatment Free
- CLL: Nodular Pattern of BM Infiltration
- CLL: Pattern of BM Infiltration
- Blood: Prognostic Indicators
- CLL and Fragile Cells
- CLL: Fragile Cells and Time to Treatment
- CLL Prognostics: CD38
- CLL Rai Stage 0: CD38
- ZAP-70 in B-CLL
- ZAP-70 in B-CLL: Detection
- ZAP-70 in B-CLL: Questions
- ZAP-70 by Flow in CLL
- ZAP-70 by Flow in CLL
- ZAP-70 by Flow in CLL
- ZAP-70: Immunohistochemistry
- CLL Rai Stage 0: ZAP-70
- CD49d in CLL
- CD49d: Clinical Role
- Time to Treatment (TTT) & Overall Survival (OS) from Diagnosis*
- CD49d in CLL
- CD49d in CLL
- Immunoglobulin Variable (IgVH) Region Mutation Status
- IgVH Sequencing
- CLL Rai Stage 0: IgVH
- Chromosome Anomalies in Chronic Lymphocytic Leukemia
- Distribution of Chromosome Anomalies in CLL Detected by FISH
- 13q-: A Microdeletion in B-CLL
- Overall Survival: By FISH Anomaly
- Risk Assessment in CLL: Summary
- Risk Assessment In CLL
- Risk Assessment
- Goals Today
- Questions?
External
link
PDF
document
Excel
document
Word
document